Evidence map›Paper›PMID 42625506›Full record

ArticleChemMedChem2026

Pyridyl-Thiazole-Thiosemicarbazones as Antitrypanosomatidae Agents: Design, Synthesis, and In Silico Profiling.

Anderson José Firmino Santos da Silva, Daiane Santiago da Cruz Olimpio, Lucas Manoel da Silva Sousa, Graziella Leite Brondani, Tacylla Lima Silva, Wéllyda Belmira de Lira Silva, Natáli Tereza Capistrano Costa, Marcelo Zaldini Hernandes, Policarpo Ademar Sales Junior, Valéria Rêgo Alves Pereira and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anderson José Firmino Santos da SilvaDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Daiane Santiago da Cruz OlimpioDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Lucas Manoel da Silva SousaDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Graziella Leite BrondaniDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Tacylla Lima SilvaDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Wéllyda Belmira de Lira SilvaDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Natáli Tereza Capistrano CostaDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Marcelo Zaldini HernandesDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.
Policarpo Ademar Sales JuniorAggeu Magalhães Institute, Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil.
Valéria Rêgo Alves PereiraAggeu Magalhães Institute, Fundação Oswaldo Cruz (FIOCRUZ), Recife, Pernambuco, Brazil.
Ana Cristina Lima LeiteDepartment of Pharmaceutical Sciences, Health Sciences Centre, Federal University of Pernambuco, Recife, Pernambuco, Brazil.ORCID https://orcid.org/0000-0002-9346-2292

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease and leishmaniasis are neglected tropical diseases caused by the trypanosomatid protozoa Trypanosoma cruzi and Leishmania spp., respectively. Currently available treatments are often insufficiently effective and lack the characteristics of ideal therapeutics. Here we report the design, synthesis, and antitrypanosomatid evaluation of 20 novel hybrid compounds incorporating pyridine, thiazole, and thiosemicarbazone scaffolds. All compounds were tested against trypomastigote and amastigote forms of T. cruzi, as well as promastigote and amastigote forms of Leishmania infantum and L. amazonensis. Cytotoxicity was assessed in L929 fibroblasts and RAW 264.7 macrophages. Compound 8 emerged as the lead, displaying an IC

Indexed as

Drug DesignLeishmaniaPyridinesThiazolesThiosemicarbazonesTrypanocidal AgentsTrypanosoma cruziAnimalsDose-Response Relationship, DrugMiceMolecular StructureParasitic Sensitivity TestsRAW 264.7 CellsStructure-Activity RelationshipPyridinesThiazolesThiosemicarbazonesTrypanocidal AgentsLeishmania spppyridinethiazolethiosemicarbazoneTrypanosoma cruzi

Identifiers

PMID42625506
PMCPMC13494692

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.